FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
1. FDA approves UZEDY® for bipolar I disorder maintenance treatment. 2. UZEDY is a long-acting injectable formulation of risperidone. 3. 1% of U.S. adults develop BD-I, highlighting market potential. 4. Teva's commitment to neuroscience advances with UZEDY's approval. 5. UZEDY may improve treatment adherence for complex mental health cases.